Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19826550 | 0.84 | GAA (0.43) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL19947462 | 0.81 | PTGER4 (0.51) | PTGER4PTGER3GSTP1MRGPRX4HDAC4 | |
| SCHEMBL18076563 | 0.79 | CYP4F2 (0.59) | PTGER4PTGER3GSTP1MRGPRX4HDAC4 | |
| SCHEMBL18076580 | 0.75 | PTGER4 (0.61) | PTGER4PTGER3GSTP1MRGPRX4HDAC4 | |
| SCHEMBL2137838 | 0.72 | MRGPRX4 (0.69) | GSTP1MRGPRX4HDAC4NAAANR4A2 | |
| SCHEMBL16346074 | 0.71 | GSTP1 (0.66) | PTGER4PTGER3GSTP1MRGPRX4HDAC4 | |
| SCHEMBL19961835 | 0.71 | MRGPRX4 (0.53) | PTGER4PTGER3GSTP1MRGPRX4HDAC4 | |
| SCHEMBL379281 | 0.71 | MAOB (0.67) | GSTP1MRGPRX4NR4A2MAOBFFAR4 | |
| SCHEMBL18076572 | 0.70 | ERN1 (0.61) | PTGER4PTGER3GSTP1MRGPRX4HDAC4 | |
| SCHEMBL19968490 | 0.70 | PTGER4 (0.52) | PTGER4PTGER3MRGPRX4HDAC4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271320-B1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LTD (AU) | 2019-10-23 | — | — | EP | disclosed |
| EP-3271320-B1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LTD (AU) | 2019-10-23 | — | — | EP | disclosed |
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-07-31 | — | — | US | disclosed |
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-07-31 | — | — | US | disclosed |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-9233938-B2 | Inhibitors of cholesterol ester transfer protein | CONCERT PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | MMP1, COL1A1, COL2A1 | PTGER4 616/4885PTGER3 644/4885GRM5 4406/4885 |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | MMP1, COL1A1, COL2A1 | PTGER4 616/4885PTGER3 644/4885GRM5 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.